RXII vs. SCYX, GRCE, KALA, CLNN, IRD, CALC, RLYB, HILS, UBX, and SCNX
Should you be buying RXi Pharmaceuticals stock or one of its competitors? The main competitors of RXi Pharmaceuticals include SCYNEXIS (SCYX), Grace Therapeutics (GRCE), KALA BIO (KALA), Clene (CLNN), Opus Genetics (IRD), CalciMedica (CALC), Rallybio (RLYB), Hillstream BioPharma (HILS), Unity Biotechnology (UBX), and Scienture (SCNX). These companies are all part of the "medical" sector.
RXi Pharmaceuticals vs.
SCYNEXIS (NASDAQ:SCYX) and RXi Pharmaceuticals (NASDAQ:RXII) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, community ranking, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.
SCYNEXIS has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500. Comparatively, RXi Pharmaceuticals has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500.
SCYNEXIS received 313 more outperform votes than RXi Pharmaceuticals when rated by MarketBeat users. Likewise, 70.04% of users gave SCYNEXIS an outperform vote while only 68.09% of users gave RXi Pharmaceuticals an outperform vote.
In the previous week, SCYNEXIS had 1 more articles in the media than RXi Pharmaceuticals. MarketBeat recorded 1 mentions for SCYNEXIS and 0 mentions for RXi Pharmaceuticals. SCYNEXIS's average media sentiment score of 1.87 beat RXi Pharmaceuticals' score of 0.00 indicating that SCYNEXIS is being referred to more favorably in the media.
54.4% of SCYNEXIS shares are held by institutional investors. Comparatively, 9.6% of RXi Pharmaceuticals shares are held by institutional investors. 2.9% of SCYNEXIS shares are held by company insiders. Comparatively, 1.0% of RXi Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
SCYNEXIS has a net margin of -425.41% compared to RXi Pharmaceuticals' net margin of -4,990.20%. SCYNEXIS's return on equity of -66.21% beat RXi Pharmaceuticals' return on equity.
SCYNEXIS has higher revenue and earnings than RXi Pharmaceuticals. SCYNEXIS is trading at a lower price-to-earnings ratio than RXi Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
SCYNEXIS beats RXi Pharmaceuticals on 14 of the 17 factors compared between the two stocks.
Get RXi Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RXII and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RXi Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:RXII) was last updated on 1/30/2025 by MarketBeat.com Staff
